跳至主要内容
临床试验/NL-OMON48911
NL-OMON48911已完成不适用

A single-center, randomized, double-blind, placebo-controlled, parallel-group studie investigating the safety, tolerability and pharmacokinetics of single- and multiple-ascending subcutaneous doses of TA-46 in healthy volunteers - TA-46 SAD and MAD dose study to investigate safety and PK

Therachon SAS0 个研究点目标入组 102 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Therachon SAS
入组人数
102

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - healthy male or female subjects
  • - female volunteers sterilized or post-memopausal
  • - 21-55 yrs, inclusive
  • - BMI: 18.0-28.0 kg/m2, inclusive
  • - non-smoking or light smokers (smoking not allowed in clinic)

排除标准

  • Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of
  • participation in another drug study within 90 days before the start of this
  • study or being a blood donor within 60 days from the start of the study. In
  • case of donating more than 1.5 liters of blood in the 10 months prior the start
  • of this study.

研究者

发起方
Therachon SAS

相似试验